Thursday, November 19, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Felicitex Therapeutics Proposes IPO

Felicitex Therapeutics Proposes IPO

in News
Felicitex Therapeutics Proposes IPO
Share on LinkedinShare on WhatsApp

Felicitex Therapeutics said in a filing that it is considering offering 2.5M units priced at $6.25 per unit. That price could change. The Natick, Massachusetts-based company hopes to list its shares on Nasdaq under the symbol FLCT.

This oncology drug development company specializes in, therapies that target dormant cancer cells. When cancer cells are dormant, they can become therapy-resistant, metastasize, and recur. Felixitex is developing treatments that target both dormant and proliferating cancers for the deadliest and most therapy-resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.

Each IPO unit would consist of one share plus two warrants to buy one share apiece at the IPO price. The warrant exercise price would be reset after 90 days of issuance to a price that is at least 50% of the IPO unit price. Underwriters would receive a 45-day option to buy up to 372K additional shares and/or up to 744K warrants to cover any over-allotments. IPO proceeds will help fund research & development subsidize general corporate purposes and provide working capital. Aegis Capital Corp. is the sole underwriter on the deal. 

Tags: CancerFelicitex TherapeuticsIPOPharmacuetical

Related Posts

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

Disney’s full year earnings prove streaming is successful
News

Disney beats earnings expectations as park attendance grows

Home Depot CFO delivers strategic update as company offers cautious forecast
News

Home Depot names Richard McPhail CEO amid leadership reshuffle

Nvidia due in Supreme Court today
News

Nvidia stock falls as execs push for Huang’s return

Warren Buffett Becomes HP Top Shareholder
News

Buffett donates $5.5 billion, urges kindness in Thanksgiving letter

Eli Lilly pledges $6 billion manufacturing plant in Alabama
News

Lilly to acquire Calytrix Bio in $1.5 billion deal

Trump pardons Founder and former CEO of Binance
News

$1.2 billion in stolen Binance crypto seized by U.S.

No Result
View All Result

Recent Posts

  • AI Has Entered the Boardroom. Who’s Overseeing It?
  • ‘Grand Theft Auto VI’ could be the biggest entertainment launch in history
  • Nvidia shares rally following earnings beat
  • Target reports its strongest sales growth in five years
  • Trump arrives in China for historic Xi, Putin meeting

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.